AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Free Cash Flow came in at -$37.4 million in Q1 2026, down 68.34% YoY from -$118.0 million in Q1 2025, and up 16.22% on a QoQ basis from -$44.6 million in Q4 2025.
AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Free Cash Flow data on file, last reported at -$37.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 68.34% year-over-year to -$37.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$189.2 million (down 32.06% YoY) and the FY2025 annual result came in at -$174.1 million, up 6.89% from the prior year.
- Free Cash Flow rose to -$37.4 million in Q1 2026, from -$44.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $241.7 million in Q2 2022 to a low of -$139.3 million in Q3 2022.
- A 5-year average of -$18.4 million and a median of -$37.4 million in 2026 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 171.08% in 2022, down 860.29% in 2022.
- Tracing ABCL's Free Cash Flow over 5 years: stood at $18.6 million in 2022, then tumbled by 283.2% to -$34.0 million in 2023, then soared by 30.59% to -$23.6 million in 2024, then plunged by 88.68% to -$44.6 million in 2025, then advanced by 16.22% to -$37.4 million in 2026.
- The last three Free Cash Flow figures came in at -$37.4 million (Q1 2026), -$44.6 million (Q4 2025), and -$61.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 23.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.79 Mn |
| Jun 30, 2026 | 23.79 Mn |
| Mar 31, 2026 | -37.35 Mn |
| Mar 31, 2026 | -37.35 Mn |
| Dec 31, 2025 | -44.59 Mn |
| Dec 31, 2025 | -44.59 Mn |
| Sep 30, 2025 | -61.52 Mn |
| Sep 30, 2025 | -61.52 Mn |
| Jun 30, 2025 | -45.77 Mn |
| Jun 30, 2025 | -45.77 Mn |
| Mar 31, 2025 | -22.19 Mn |
| Mar 31, 2025 | -22.19 Mn |
| Dec 31, 2024 | -23.63 Mn |
| Dec 31, 2024 | -23.63 Mn |
| Sep 30, 2024 | -47.40 Mn |
| Sep 30, 2024 | -47.40 Mn |
| Jun 30, 2024 | -50.08 Mn |
| Jun 30, 2024 | -50.08 Mn |
| Mar 31, 2024 | -65.85 Mn |
| Mar 31, 2024 | -65.85 Mn |